NM8074 not checked

NovelMed Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
8 active
9 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“NM8074 will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.”In the company’s words, NCT05646524 on ClinicalTrials.gov
Tested for
Paroxysmal Nocturnal Hemoglobinuria (2 trials), PNH - Paroxysmal Nocturnal Hemoglobinuria, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Dermatomyositis, aHUS - Atypical Hemolytic Uremic Syndrome, IgA Nephropathy, C3 Glomerulopathy
Main trialPhase 2
“This is a Phase II, open-label study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 administered intravenously to adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).”In the company’s words, NCT05646524 on ClinicalTrials.gov
Given with
Soliris (Alexion Pharm)Other companies’ drugs in its trials

Other drugs for Paroxysmal Nocturnal Hemoglobinuria

All 23 drugs for Paroxysmal Nocturnal Hemoglobinuria

Coming up8

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting Aug 2027 Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy
Phase 2Not yet recruiting Sep 2027 Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2Not yet recruiting Oct 2027 Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
Phase 2Not yet recruiting Nov 2027 Study of NM8074 in Patients with Dermatomyositis (DM)
Phase 2Not yet recruiting Jul 2029 Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris
Phase 2Not yet recruiting Apr 2030 Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy
Phase 2Not yet recruiting Dec 2030 Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
Phase 1/2Not yet recruiting Aug 2029 Study of NM8074 in Adult C3 Glomerulopathy Patients
Phase 1Completed 15 Jun 2022 First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow NM8074

Following is part of Solo: you see every change to NM8074 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in